Drugs.com Clinical Trial ResultsOriginal article
FDA Grants Fast Track Designation to SOTIO’s SOT109, a CDH17-targeting ADC for Colorectal Cancer
RegulatorySOT109Positive
AI Analysis
Summary
SOTIO Biotech announced that the FDA granted Fast Track Designation to SOT109, a CDH17-targeting antibody-drug conjugate (ADC) for colorectal cancer treatment.
Outcome Details
Fast Track Designation granted by FDA
Importance:6/10
Sentiment:
0.70
Fast Track DesignationADCCDH17-targetingColorectal CancerFDAclinical-stage
Related Companies
Read the original article
Published by Drugs.com Clinical Trial Results on July 14, 2026 6:07 AM